55 results about "Corpus luteum" patented technology

The invention relates to an ovarian reserve hypofunction prediction method based on multi-data fusion, and the technical scheme comprises the following steps: regularly collecting biomarker data related to ovarian reserve, including anti-mullerian canal hormone AMH, follicle stimulating hormone FSH, luteinizing hormone LH, estradiol E2, and ultrasonic image data including follicle quantity and ovarian volume; acquiring dynamic change curve data and capturing the change trend of the ovarian reserve function when the acquisition time point covers the key stage of the menstrual cycle; analyzing the biomarker data acquired for multiple times by using an LSTM deep learning model, and modeling a change trend of the ovarian reserve function of each patient along with time; by analyzing the periodic fluctuation of AMH and FSH biomarkers, the decline time node of the ovarian reserve function in the future is predicted; and on the basis of the LSTM deep learning model of S1.1, performing personalized risk assessment in combination with individual characteristics of patients including age, genes, lifestyles and disease histories.

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The invention provides an application of a CTH inhibitor and / or an xCT inhibitor in preparation of a medicine for inhibiting mammal embryo implantation, and relates to the technical field of medicines. The application effect of a cystathionine-gamma-lyase (CTH) inhibitor and / or a solute carrier family 7 member 11 (xCT) inhibitor in inhibition of mammalian embryo implantation is verified through research. The research result shows that the xCT inhibitor and / or the CTH inhibitor can obviously inhibit proliferation of corpus luteinized granular cells and secretion of progesterone of a model mouse; meanwhile, by injecting the xCT inhibitor and / or the CTH inhibitor into the mouse model in vivo, ovary ovulation and the maturation rate of the ovulated oocyte nucleus can be remarkably inhibited, functional corpus luteum formation and embryo implantation can be remarkably reduced, and then a new thought and method are provided for development of contraceptive drugs.

The invention provides application of a traditional Chinese medicine composition in preparation of a medicine for preventing and / or treating ovarian dysfunction, and belongs to the technical field of biological medicine. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 8-10 parts of American ginseng, 2-4 parts of pseudo-ginseng, 55-65 parts of kudzuvine root, 42-48 parts of coptis chinensis, 42-48 parts of scutellaria baicalensis, 14-16 parts of stiff silkworm, 14-16 parts of rhizoma zingiberis, 42-48 parts of bitter gourd and 55-65 parts of rhizoma anemarrhenae. The traditional Chinese medicine composition has the effects of increasing the number of follicles and corpus luteum, restoring the duration of an estrus cycle and restoring the levels of serum hormones and sex hormone receptors. The traditional Chinese medicine composition provided by the invention provides a new means for preventing and treating ovarian dysfunction.

The invention discloses application of cannabidiol in preparation of a medicine for treating polycystic ovarian syndrome. Experiments on mice with dihydrotestosterone-induced polycystic ovarian syndrome show that cannabidiol can relieve the disorder state of the estrus cycle, improve the change of ovarian polycystic samples, reduce the number of atresia follicles, increase the number of corpus luteum, improve the level of serum progestational hormone, improve glucose and lipid metabolism and relieve anxiety for the first time; the traditional Chinese medicine composition can be used for treating polycystic ovarian syndrome. The invention provides a brand new thought for research and development of medicines for treating the polycystic ovarian syndrome, and has a wide application prospect.

This invention discloses an in vitro maturation culture medium for ferret oocytes and its preparation method, belonging to the field of animal embryo engineering technology. It comprises the following components: TCM199 basal culture medium, 50 mL fetal bovine serum, 25 IU follicle-stimulating hormone, 25 IU luteinizing hormone, 0.5 mg 17β-estradiol, 0.005 mg epidermal growth factor, 12.1 mg sodium pyruvate, 0.2 mM cysteine, 0.1 mM cysteine, 0.030 g penicillin, 0.025 g streptomycin sulfate, as well as an antioxidant complex, a combination of growth factors, and extracellular matrix components. This invention provides a comprehensive and suitable nutritional environment for ferret oocytes by precisely formulating a composite culture medium containing multiple key components. Specifically, the hormone combination at specific concentrations accurately simulates the in vivo physiological environment, effectively regulating the oocyte maturation process; multiple growth factors work synergistically to promote oocyte growth, development, and differentiation; and the addition of the antioxidant complex effectively eliminates free radicals generated during in vitro culture, reducing oxidative stress damage to oocytes.

The invention discloses an additive for resisting cow ovarian aging and its application. The additive is made of a composition of anthocyanidins, glycyrrhizic acid and wolfberry glycopeptide. When the composition is used in clinical veterinary treatment of cow ovarian aging, the role of primary cow ovarian granulosa cells is clarified through transcription, which is mainly involved in regulating programmed cell death, Ras protein signal transduction, tissue development, cell serine, tryptophan kinase activity, MAPK signaling pathway, PI3K-AKT signaling pathway, and laser confocal results show that the composition can significantly reduce the production of mitochondrial reactive oxygen; at the same time, the therapeutic effect on the persistent corpus luteum of the main cow is achieved by improving the intestinal flora structure, and more specifically, the colony is significantly changed upstream at the genus and species level; B-ultrasound results reveal that for a persistent corpus luteum cow, more large follicles can be detected on the ovaries after one month of gavage with the additive composition.

The present invention belongs to the field of biomedical technology, and discloses the application of putrescine in the preparation of a drug for preventing and treating OHSS. Starting from the pathological mechanism of OHSS, an OHSS model was established with C57BL / 6 female mice, and putrescine was given through natural drinking water to explore its preventive and therapeutic effects on OHSS. The results showed that putrescine could reduce the ovarian weight, ovarian somatic ratio, number of congested follicles, number of corpora lutea, and VEGF expression level in the OHSS model, and would not have an adverse effect on the litter size of mice, indicating that putrescine can effectively prevent and treat OHSS. The present invention predicts to provide a new intervention approach and candidate drug for the clinical prevention of OHSS.

The invention belongs to the technical field of functional foods and health foods, and particularly relates to a composition for improving premature ovarian failure and a preparation method thereof. The composition comprises the following components in parts by weight: 5-15 parts of orange osmanthus pollen, 4-12 parts of flaxseed concentrated powder, 2-8 parts of black-bone chicken peptide, 4-20 parts of rehmannia powder, 2-10 parts of cistanche powder and 1-5 parts of lemon concentrated powder. The composition for improving premature ovarian failure prepared by the invention can reduce the content of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in the serum of a premature ovarian failure rat induced by cyclophosphamide and increase the content of estradiol (E2), thereby achieving the effect of improving premature ovarian failure.

The invention discloses application of pyruvic acid in regulation and control of follicular development of mammals. According to the invention, pyruvic acid is taken as a research object, and the influence of pyruvic acid on oestrus day age, follicle development and granular cell proliferation and apoptosis of mammals is researched by adopting molecular and cell biology methods: HE staining and Tunel staining find that the pyruvic acid significantly increases the number of corpus luteum and luteum follicles and reduces the apoptosis of granular cells; qRT-PCR and WB results show that the mRNA and protein levels of the key genes of the proliferation pathway are up-regulated after pyruvic acid treatment and the mRNA and protein levels of the key genes of the apoptosis pathway are down-regulated after pyruvic acid treatment. In conclusion, pyruvic acid can promote the development of ovarian follicles by promoting granular cell proliferation and inhibiting granular cell apoptosis, so as to promote mouse oestrus.

The invention discloses a pharmaceutical composition for treating corpus luteum insufficiency type infertility as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The technical problem to be solved is to provide the pharmaceutical composition for treating the LPD type infertility, which is simpler in formula, lower in cost and better in treatment effect. According to the technical scheme, the pharmaceutical composition is prepared from the following raw materials: codonopsis pilosula, astragalus membranaceus, fried rhizoma atractylodis macrocephalae, angelica sinensis, semen cuscutae, fried eucommia ulmoides, fried teasel root, honey-fried licorice root, processed radix aconiti carmichaeli and cornu cervi degelatinatum. The pharmaceutical composition provided by the invention can improve ovarian injury, ferroptosis phenomenon, embryo implantation disorder, uterine artery blood perfusion and the like caused by LPD, and is helpful for various pathological problems related to LPD.

The invention discloses a traditional Chinese medicine composition for treating ovarian reserve function decline. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 10-20 parts of radix rehmanniae preparata, 10-20 parts of radix rehmanniae, 8-15 parts of radix glehniae, 10-20 parts of radix ophiopogonis, 5-10 parts of colla corii asini, 8-15 parts of rhizoma dioscoreae, 8-15 parts of herba dendrobii, 8-15 parts of tortoise plastron, 8-15 parts of semen euryales, 8-15 parts of semen cuscutae and 8-15 parts of radix morindae officinalis. The traditional Chinese medicine composition can improve follicle development disorder and sex hormone disorder of rats with ovarian reserve function insufficiency induced by cyclophosphamide, the number of atresia follicles and corpus luteum is obviously reduced, and the traditional Chinese medicine composition has a good treatment prospect.

Tracking ovulatory hormone levels is key to detecting fertility windows and providing actionable information for facilitating or preventing conception, as well as assessing and managing infertility and other conditions associated with hormone imbalances. Conventional fertility methods suffer drawbacks associated with invasive sampling, inadequate prediction accuracies, or repetitive user intervention. To overcome these and other limitations, the present Applicants developed a wearable device for contemporaneous monitoring of estradiol, progesterone, and luteinizing hormone and physiological biomarkers (temperature, pH). Flexible field-effect transistors functionalized with biomarker-specific aptamers enabled sensitive and selective determination of the three principal ovulatory hormones across physiological ranges in artificial human sweat. By including an on-demand iontophoretic sweat sampling feature, the present Applicants established an integrated wearable platform for high-accuracy, minimally invasive, rapid, and personalized ovulatory status monitoring.

The invention belongs to the technical field of biological medicine manufacturing, and particularly relates to a pharmaceutical preparation for improving ovarian functions and a preparation method thereof. The pharmaceutical preparation comprises the following raw materials in parts by weight: 12-25 parts of berberine hydrochloride, 8-16 parts of shionone, 5-10 parts of dicliptera chinensis polysaccharide, 10-20 parts of a diluent, 5-9 parts of an adhesive and 1-6 parts of a lubricant. According to the pharmaceutical composition, berberine hydrochloride, shionone and dicliptera chinensis polysaccharide are compounded, sexual cycle disorder caused by the polycystic ovarian syndrome is adjusted in a synergistic interaction mode, insulin resistance is improved, indexes such as luteinizing hormone (LH), follicle-stimulating hormone (FSH) and LH / FSH are remarkably improved, and the pharmaceutical composition has the application potential of treating the polycystic ovarian syndrome and has good application prospects. And the market prospect is wide.

This invention belongs to the field of biomedical technology, specifically relating to the application of a composition in the preparation of a drug for the prevention and treatment of polycystic ovary syndrome (PCOS). The composition comprises bovine spleen peptide and adenosine; the mass ratio of bovine spleen peptide to adenosine is 1:(1-2.5). Bovine spleen peptide, as a bioactive polypeptide, significantly improves insulin resistance associated with PCOS by targeting and activating the PI3K-Akt signaling pathway and promoting insulin receptor substrate phosphorylation. Adenosine, as a natural bioactive substance, significantly reduces serum luteinizing hormone and testosterone levels in rats and increases follicle-stimulating hormone levels, thereby effectively alleviating hyperandrogenism symptoms such as hirsutism and acne in PCOS. Furthermore, this composition can significantly improve polycystic pathological changes in the ovarian tissue of model rats, reduce the number of cystic dilated follicles, restore the granulosa cell layer structure, alleviate ovarian stromal hyperplasia, and promote normal follicular development.

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating polycystic ovarian syndrome. The traditional Chinese medicine composition comprises spina gleditsiae, polygonum cuspidatum, dandelion, sargentgloryvine stem, codonopsis pilosula, chinaroot greenbrier, radix paeoniae rubra, salvia miltiorrhiza, lindera aggregata and corydalis tuber. Experiments show that the traditional Chinese medicine composition can obviously inhibit the weight increase of the ovary of a rat with the polycystic ovarian syndrome; moreover, the content of luteinizing hormone and testosterone in serum of a rat with the polycystic ovarian syndrome can be reduced, and the traditional Chinese medicine composition has a good effect of treating the polycystic ovarian syndrome.

The purpose of the present invention is to provide an absorbent article and a test paper for the absorbent article in which a period suitable for natural pregnancy can be grasped at an earlier timing than before. An absorbent article according to the present disclosure has a test strip using immunochromatography for detecting luteinizing hormone (LH) from leucorrhea, the test strip being configured to estimate that a wearer of the absorbent article is in a period from five days before an ovulation day to the day of the ovulation day.

The invention relates to a traditional Chinese medicine effective component screening method based on a chemical fingerprint spectrum and multi-omics combined analysis. The method comprises the following steps: preparing a semen cuscutae-fructus lycii medicine pair extract and establishing a UPLC-Q-TOF-MS / MS chemical fingerprint spectrum; detecting the levels of estradiol, luteinizing hormone, anti-mullerian hormone and follicle-stimulating hormone in the premature ovarian insufficiency animal model; screening characteristic components related to the drug effect through multivariate statistical analysis; performing transcriptome sequencing on the ovarian tissue, and combining GO / KEGG analysis to determine a key pathway; integrating database prediction targets and differential genes, screening hub genes and constructing a protein interaction network; and finally verifying the binding activity of the candidate component and the core target protein through molecular docking and molecular dynamics experiments. According to the invention, systematic screening and action mechanism analysis of drug effect related components are realized, and a new technical approach is provided for mass marker determination and estrogen simulating action research of the dodder-wolfberry drug pair.

A grading and counting method for follicles and corpus luteum growing in ovaries of rats relates to the technical field of image analysis, and comprises the following steps: scanning ovary staining sections; identifying needed ovarian tissues and converting the needed ovarian tissues into a first region of interest ROI1; screening out growing follicles and corpus luteum meeting requirements on ROI1; and identifying and marking the screened growing follicles meeting the requirements as primary follicles, secondary follicles, tertiary follicles and follicles which cannot be graded, identifying and marking the screened corpus luteum meeting the requirements as newborn corpus luteum, recent corpus luteum, old corpus luteum and corpus luteum which cannot be graded, and finally counting to obtain the number of the follicles and corpus luteum of each level. According to the invention, artificial intelligence of classification and counting of ovarian growth follicles and corpus luteum of rats can be realized, and rapid and accurate batch operation is realized.

The invention belongs to the technical field of aquaculture, and particularly relates to an aquatic population breeding and seedling raising method based on water temperature-hormone cooperative regulation and control and application of the aquatic population breeding and seedling raising method based on water temperature-hormone cooperative regulation and control. The growth regulator is used for enhancing the reproduction promoting effect of luteinizing hormone releasing hormone or analogues thereof; propagation promotion refers to promotion of oocyte growth, promotion of yolk accumulation, shortening of ovary development cycle and improvement of oviposition rate. The invention discovers and verifies the fish breeding promoting effect of the butyric acid and the sodium salt thereof for the first time, wherein the butyric acid and the sodium salt thereof can enhance luteinizing hormone release hormone.

The present invention relates to assisted reproductive management technologies common to animal husbandry, more specifically technologies and processes enabling timed artificial insemination (TAI) and timed embryo transfer (TET), superovulation for multiple ovulation embryo transfer (MOET) and superstimulation for ovum pickup (OPU) prior to in-vitro fertilization. More specifically, the present invention is directed to simplified, single-injection methods and formulations to control the onset of estrus and ovulation occurring within the reproductive technologies described above. The formulations focus on progesterone (P4) and luteinizing hormone (LH).

The invention discloses application of cubilose in preparation of a product for improving polycystic ovarian syndrome. The cubilose can effectively improve the hormone level of a patient with the polycystic ovarian syndrome, remarkably improve the levels of follicle-stimulating hormone and estradiol, reduce the levels of luteinizing hormone and testosterone and reduce the ratio of the content of the luteinizing hormone to the content of the follicle-stimulating hormone.

The application belongs to the technical field of aquaculture, and particularly relates to a water temperature-hormone synergistically regulated aquaculture population breeding and hatching method and application. The growth regulator is butyric acid or sodium butyrate. The growth regulator is used to enhance the breeding promotion effect of luteinizing hormone-releasing hormone or its analogs. The breeding promotion refers to promoting the growth of oocytes, promoting yolk accumulation, shortening the ovarian development cycle, and improving the egg production rate. It is found and verified for the first time that butyric acid and its sodium salt can enhance the breeding promotion effect of luteinizing hormone-releasing hormone.

The invention relates to application of butyric acid in preparation of a medicine for treating polycystic ovarian syndrome. According to the application disclosed by the invention, the treatment mechanism of the butyric acid for treating the polycystic ovarian syndrome is researched for the first time, and it is found that the specific butyric acid receptor Gpr109a of granular cells on an ovary can be remarkably increased and ferroptosis of the granular cells on the ovary can be inhibited by oral administration of the butyric acid, so that the cyst number of a PCOS mouse is reduced, the luteum number is increased, and the purpose of treating the PCOS is achieved. It is found that the effective dosage of butyric acid in the medicine is 302.5 mg / kg-907.5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / kg-90. 5 mg / male hormones return to normal, and the like. A brand new thought is provided for research and development of medicines for treating the polycystic ovarian syndrome, and the application prospect is wide.

The invention discloses a novel application of a compound MLN4924 (Pevonedat) in preparation of a medicine for improving oocyte quality and treating related diseases, and belongs to the technical field of biological medicines. PCOS animal model experiments prove that the reproductive endocrine indexes of model animals can be remarkably improved by applying the MLN4924, and the reproductive endocrine indexes are specifically represented by restoring the regularity of an estrus cycle and reducing the levels of testosterone and luteinizing hormone in serum; meanwhile, the fertility is improved, and the birth number is increased. In the aspect of oocyte quality, the treatment can increase the number of normal oocytes in an ovary, improve the first polar body discharge rate of in-vitro maturation of the oocytes and improve the blastocyst formation rate after in-vitro fertilization. A further mechanism research shows that the MLN4924 can inhibit the plasmosis of the TRIM21 in the ovarian granular cells and down-regulate the expression level of the protein of the TRIM21. The results show that the MLN4924 provides a new drug choice for developing related diseases for treating polycystic ovarian syndrome (PCOS) and improving oocyte quality.

The invention discloses an application of a sheep placenta extract in preparation of a medicine for improving polycystic ovarian syndrome, and relates to the technical field of biological medicine, the medicine is used for improving endocrine disorder and abnormal inflammation caused by the polycystic ovarian syndrome, and particularly for reducing the plasma androgen level and increasing the plasma estrogen level and the plasma progestational hormone level; the level of an inflammatory factor TNF-alpha is reduced, and the level of an inflammatory factor IL-10 is increased. The sheep placenta extract can improve ovarian polycystic lesions caused by polycystic ovarian syndrome (PCOS) in a targeted manner, and experiments show that after intervention of the sheep placenta extract, the number of macroscopic cystic follicles in rat ovary is reduced, the weight of the ovary with abnormal weight gain is remarkably reduced, the cystic follicle ratio in ovarian histopathology detection is greatly reduced, and the sheep placenta extract has a good application prospect. The ratio of the number of the corpus luteum is closer to normal, and the pathological injury of the polycystic ovarian syndrome is repaired from the organ level.

The invention discloses application of P-G3 in preparation of a medicine for improving fertility of obese women. The invention provides a first double-target treatment new drug P-G3 (third-generation PAMAM) for obese female infertility, which can reverse double injuries of peripheral ovarian fat accumulation and central reproductive axis imbalance (hypothalamic GnRH neuron low activity) at the same time, reduce fat around ovaries in a targeted manner, improve the curative effect of the ovaries, and improve the curative effect of the ovaries. The problems of female follicular dysplasia caused by obesity, low secretion level of luteinizing hormone (LH) and weak reaction of hypothalamus-pituitary axis (HP) to Kisspeptin-54 are obviously improved, and the fertility of obese women is improved.

The utility model discloses a cattle and horse ovary simulation teaching model, which comprises a hard shell used for simulating ovary, an elastic balloon is arranged in the hard shell, a booster pump can inflate gas or liquid into the elastic balloon through a catheter, and after the elastic balloon is expanded, the outer wall of the elastic balloon protrudes through an opening on the wall surface of the hard shell so as to simulate follicles. Meanwhile, a soft outer surface layer is laid on the outer wall of the hard ball body, and protrusions are arranged on the soft outer surface layer to simulate the corpus luteum formed after follicle rupture and ovulation. A connecting body is sleeved on the guide pipe; the connecting body comprises an elastic rod and a hard rod which are nested inside and outside, and the elastic rod is connected with the hard shell, so that the hard shell has two states, namely a movable state when the elastic rod extends out of the hard rod and a fixed state when the elastic rod extends into the hard rod. According to the utility model, after the hard rod is fixed, the sight line of a trainee is separated from the hard shell, so that follicle and corpus luteum identification and palpation training and ovary grasping training can be realized in two states of fixing and moving the ovary position.

The invention relates to application of wood frog seeds and extracts thereof in preparation of products for improving fertility, and belongs to the technical field of reproductive health products. The wood frog seeds are dry or fresh ova of wood frogs and are used in the form of original shapes, crushed materials, freeze-dried powder or extracts, the extracts comprise wood frog seed oil obtained through ethanol extraction, supercritical carbon dioxide extraction or a physical squeezing method, and the application of the wood frog seeds and the extracts thereof can remarkably improve the female pregnancy rate, improve the quantity and quality of follicles and improve the survival rate of female pregnancy. The traditional Chinese medicine composition is especially suitable for improving testis, epididymis or kidney function impairment caused by high fat diet. The method has remarkable advantages in the aspect of promoting the fertility function, the quality of male sperms can be improved, the development and luteal function of female follicles can also be improved, particularly, the supercritical extraction technology has the effect of enriching active ingredients of wood frog seeds, the sperm motility and the follicle number can be remarkably improved, and the survival rate of the sperms is increased. The invention provides a new scheme for developing natural and efficient reproduction improvement products.

Disclosed herein are devices, systems, methods and kits for performing immunoassay tests to detect for at least progesterone or analytes of progesterone on a sample in association with diagnosing problems and issues associated with corpus luteum functionality. The immunoassay devices and methods may be used in conjunction with diagnostic reader systems and / or a base unit for obtaining a sensitive readout of the immunoassay results. The methods disclosed herein may also incorporate steps associated with evaluating the urine of a sample for the presence of an estrogen metabolite and / or luteinizing hormone.